January 9, 2023

Press release

FluoGuide releases positive interim result of FG001 in head and neck cancer

Copenhagen, Denmark, 9 January 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce the positive interim result of... [Read more]

November 24, 2022

Press release

FluoGuide A/S publishes interim report for the period January – September 2022

Copenhagen, Denmark, 24 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

November 21, 2022

Press release

FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer

Copenhagen, Denmark, 21 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company has enrolled... [Read more]

November 8, 2022

Press release

FluoGuide reaches milestone with FG001 for phase III clinical supply

Copenhagen, Denmark, 8 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the first large scale... [Read more]

November 6, 2022

Press release

FluoGuide releases positive interim result of FG001-CT002, a phase IIa trial evaluating FG001 in patients with non-small cell lung cancer (NSCLC) undergoing surgery

Copenhagen, Denmark, 6 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 lights up in... [Read more]

October 20, 2022

Press release

FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer

Copenhagen, Denmark, 20 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the first patient has... [Read more]

October 6, 2022

Press release

Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chief... [Read more]

October 3, 2022

Press release

The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress

Copenhagen, Denmark, 3 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform of presentation of the outstanding... [Read more]

September 6, 2022

Press release

FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark, 6 September 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received... [Read more]